Innate Pharma (IPHA) said Monday its investigational new drug application has been cleared by the US Food and Drug Administration for a phase 1 trial of IPH4502, an antibody drug conjugate targeting Nectin-4 in solid tumors.
The trial, to start in coming months, will include dose escalation and optimization sections and will assess the safety, tolerability and preliminary efficacy of IPH4502 as a single agent, the company said.
Innate Pharma shares were more than 7% higher in premarket trading.
Price: 2.2600, Change: +0.15, Percent Change: +7.11
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。